Feature Channels: Immunology

Filters close
Newswise: The cellular response that protects pigs from COVID-19
Released: 20-Jan-2022 12:05 PM EST
The cellular response that protects pigs from COVID-19
Iowa State University

Studies since the start of the pandemic have noted that pigs exposed to the coronavirus don’t show clinical signs of disease nor do they transmit the virus to other animals. Iowa State University scientists have uncovered important clues that shed light on why pigs don’t get sick, and the discovery could lead to better treatments for COVID-19 in humans.

   
Released: 20-Jan-2022 10:05 AM EST
Cancer treatment may inhibit immune response to COVID-19 vaccination
Mayo Clinic

A study by researchers at Mayo Clinic Cancer Center has found that patients with cancer who receive chemotherapy ― and some targeted therapies, such as CDK4/6 inhibitors and therapies targeted at B cells ― may mount an inadequate immune response to COVID-19 vaccination. The findings are published in Mayo Clinic Proceedings.

Released: 19-Jan-2022 4:05 PM EST
Persistent T cell response to omicron after infection and vaccination
Karolinska Institute

The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2.

Newswise: La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.
Released: 18-Jan-2022 10:00 AM EST
La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.
La Jolla Institute for Immunology

La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement. The agreement marks another milestone in one of the most enduring industry-academic collaborations in the world.

Newswise: Wistar Scientists Identify Therapeutic Target for Epstein-Barr Virus
17-Jan-2022 5:00 AM EST
Wistar Scientists Identify Therapeutic Target for Epstein-Barr Virus
Wistar Institute

A new study by Wistar researchers has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).

Newswise: Boosting T cells improves survival in mice with glioblastoma
Released: 15-Jan-2022 3:05 PM EST
Boosting T cells improves survival in mice with glioblastoma
Washington University in St. Louis

A new study from Washington University School of Medicine in St. Louis shows that treatment with an immune-boosting protein called interleukin 7 (IL-7) in combination with radiation improves survival in mice with glioblastoma. The study in mice suggests promise for a phase 1/2 clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine that is investigating a long-acting type of IL-7 in patients with glioblastoma.

Newswise: Biologists Pinpoint Key Factor in Immune System Response to Viral Infection
Released: 13-Jan-2022 8:05 PM EST
Biologists Pinpoint Key Factor in Immune System Response to Viral Infection
University of California San Diego

Researchers studying how small worms defend themselves against pathogens have discovered a gene that acts as a first-line response against infection. They identified “ZIP-1” as a centralized hub for immune response, a finding could have implications for understanding human immunity against viruses.

13-Jan-2022 11:05 AM EST
Study identifies Epstein-Barr as a leading candidate for cause of Multiple Sclerosis
Uniformed Services University of the Health Sciences (USU)

A new study published Jan. 13 in Science reports that Epstein-Barr virus infection – known for causing mononucleosis or “mono,” could be a primary cause for multiple sclerosis.

Newswise: Research shows that human immune system uses ancient family of cell death proteins also found in bacteria
13-Jan-2022 12:00 PM EST
Research shows that human immune system uses ancient family of cell death proteins also found in bacteria
Dana-Farber Cancer Institute

The human immune system, that marvel of complexity, subtlety, and sophistication, includes a billion-year-old family of proteins used by bacteria to defend themselves against viruses, scientists at Dana-Farber Cancer Institute and in Israel have discovered.

Newswise:Video Embedded macrophages-in-the-artery-wall-smell-their-surroundings
VIDEO
10-Jan-2022 11:55 AM EST
Macrophages in the artery wall 'smell' their surroundings
La Jolla Institute for Immunology

An artery is not like a nose. Or is it? Scientists at La Jolla Institute for Immunology (LJI) have discovered that immune cells in arteries can "sniff" out their surroundings and cause inflammation.

Released: 11-Jan-2022 12:10 PM EST
New, targeted therapy inhibits specific immune cells associated with lupus nephritis
Bar-Ilan University

A new, targeted therapy, developed by researchers from the Azrieli Faculty of Medicine of Bar-Ilan University, the Albert Einstein College of Medicine, the University of Houston, and the pharmaceutical company Equillium, together with several other academic collaborators, inhibits specific immune cells associated with lupus nephritis, and was effective in improving kidney inflammation in animal models of lupus and lupus nephritis. The new approach could serve as an alternative to current treatments targeting multiple immune cells, and provide a more effective and potentially personalized remedy for lupus nephritis. The development was recently reported in the Journal of Clinical Investigation.

Released: 11-Jan-2022 11:50 AM EST
Moffitt Researchers Discover Mechanism Controlling Tertiary Lymphoid Structure Formation in Tumors
Moffitt Cancer Center

Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures. However, little is known about how tertiary lymphoid structures form. In a new article published in Immunity, Moffitt Cancer Center researchers report on the molecular and cellular mechanisms that control tertiary lymphoid structure formation within tumors.

Released: 11-Jan-2022 9:45 AM EST
Penn Medicine Researchers Develop New Method to Increase Effectiveness of Nanomedicines
Perelman School of Medicine at the University of Pennsylvania

Researchers at Penn Medicine have discovered a new, more effective method of preventing the body’s own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy’s effectiveness.

Released: 7-Jan-2022 3:15 PM EST
There is evidence that the vaccines work against the Omicron variant to some degree, despite claim made by columnist
Newswise

There is growing evidence that the currently available MRNA vaccines provide some protection against the Omicron variant (B.1.1.529) of the SARS-COV-2 virus, the coronavirus that causes COVID-19. According to the CDC, preliminary results for Omicron from South Africa showed that the Pfizer vaccine provided 70% protection against COVID-19 hospitalization and 33% against infection, during the current Omicron wave. Granted, the protection is reduced compared with the Delta variant (93% for hospitalization and 80% for infection).

Released: 6-Jan-2022 2:55 PM EST
Vaccine-like mRNA Injection Can Be Used to Make CAR T cells in the Body
Perelman School of Medicine at the University of Pennsylvania

An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

Newswise: LJI and Charles River Laboratories to collaborate on COVID-19 research
Released: 6-Jan-2022 6:00 AM EST
LJI and Charles River Laboratories to collaborate on COVID-19 research
La Jolla Institute for Immunology

Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system respond to SARS-CoV-2, the virus that causes COVID-19.

Released: 4-Jan-2022 5:05 PM EST
أبحاث مايو كلينك تجد أن الجهاز المناعي يستجيب لعلاج السرطان بالحمض النووي الريبوزي المرسال
Mayo Clinic

مدينة روتشستر، ولاية مينيسوتا - تُظهر أبحاث مايو كلينك أن إضافة علاج الحمض النووي الريبوزي المرسال (mRNA) يحسن الاستجابة للعلاج المناعي للسرطان لدى المرضى الذين لم يستجيبوا للعلاج. ويستخدم العلاج المناعي جهاز المناعة في الجسم للوقاية من السرطان ومكافحته والقضاء عليه. كما نُشرت الدراسة في أبحاث مناعة السرطان، إحدى مجلات الجمعية الأمريكية لأبحاث السرطان.

Released: 4-Jan-2022 5:05 PM EST
妙佑医疗国际研究发现免疫系统对癌症的mRNA治疗有应答
Mayo Clinic

妙佑医疗国际(Mayo Clinic)的研究表明,添加信使的RNA(核糖核酸)或称mRNA疗法可以改善对治疗无反应的患者对癌症免疫疗法的应答。免疫疗法利用人体的免疫系统来预防、控制和消除癌症。这项研究发表于美国癌症研究协会的期刊《癌症免疫学研究》。

Released: 4-Jan-2022 5:05 PM EST
Pesquisa da Mayo Clinic descobre que o sistema imunológico responde ao tratamento com mRNA para o câncer
Mayo Clinic

a adição da terapia com RNA mensageiro ou mRNA, melhora a reposta da imunoterapia ao câncer nos pacientes que não estavam respondendo ao tratamento, demonstra uma pesquisa da Mayo Clinic. A imunoterapia utiliza o sistema imunológico para prevenir, controlar e eliminar o câncer. O estudo está publicado no Cancer Immunology Research, uma revista médica da Associação Americana para Pesquisa do Câncer.

Released: 4-Jan-2022 5:05 PM EST
Estudio de Mayo Clinic descubre que el sistema inmunitario responde a tratamiento oncológico con ARN mensajero
Mayo Clinic

Añadir la terapia con ARN mensajero mejora la respuesta a la inmunoterapia contra el cáncer en los pacientes que no respondieron al tratamiento, revela un estudio de Mayo Clinic. La inmunoterapia utiliza al sistema inmunitario para prevenir, controlar y eliminar el cáncer. El estudio se publicó en Cancer Immunology Research (Investigación Inmunológica sobre el Cáncer), revista de la Asociación Americana de Investigación sobre el Cáncer.

Newswise: More than two decades of UTSW research paves way for first-in-kind drug
Released: 3-Jan-2022 2:05 PM EST
More than two decades of UTSW research paves way for first-in-kind drug
UT Southwestern Medical Center

A first-in-kind immune-modulating drug that arose from decades of basic research at UT Southwestern Medical Center has received approval from the U.S. Food and Drug Administration as a new treatment for adults with a form of myasthenia gravis. This rare and chronic autoimmune disease is characterized by debilitating and potentially life-threatening muscle weakness.

Newswise: Strange DNA structures may drive cancer development
Released: 23-Dec-2021 10:45 AM EST
Strange DNA structures may drive cancer development
La Jolla Institute for Immunology

Scientists at the La Jolla Institute for Immunology (LJI) have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.

Newswise: A Breakthrough in Probiotic Therapy – Personalized Probiotics (Dispensing) Machine for a Balanced and Enhanced Immune System
Released: 23-Dec-2021 8:55 AM EST
A Breakthrough in Probiotic Therapy – Personalized Probiotics (Dispensing) Machine for a Balanced and Enhanced Immune System
Chulalongkorn University

MED-CU has invented a Personalized Probiotics (Dispensing) Machine to deliver live microorganisms that have health benefits to treat patients with unclear health problems and those with microbial imbalances or “dysbiosis”.

Released: 23-Dec-2021 8:05 AM EST
SARS-CoV-2 goes ‘underground’ to spread from cell to cell
Ohio State University

The virus that causes COVID-19 has adopted some stealth moves to stay alive and kicking, and one secret to its success is hiding from the immune system by spreading through cell-to-cell transmission, a new study has found.

Released: 22-Dec-2021 12:50 PM EST
T cells: No time to die
University of Basel

They are at the forefront in the fight against viruses, bacteria, and malignant cells: the T cells of our immune system.

Newswise: UTSW working to reprogram cells to strengthen immunity in geriatric patients
Released: 21-Dec-2021 12:05 PM EST
UTSW working to reprogram cells to strengthen immunity in geriatric patients
UT Southwestern Medical Center

What if the key to aging well lies in reprogramming immune system cells to strengthen them against infections and cancer? Researchers at UT Southwestern are working to find out.

Released: 17-Dec-2021 10:05 AM EST
New Study Adds More Evidence for Omicron Immune Evasion
Columbia University Irving Medical Center

A new study from COVID researchers at Columbia and the University of Hong Kong adds more evidence that the omicron variant can evade the immune protection conferred by vaccines and natural infection.

Released: 16-Dec-2021 12:30 PM EST
Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers
University of Maryland School of Medicine

Research Shows Vaccine Has 90 Percent Efficacy at Preventing Infections; Moderate to Severe Disease Occurred Only in Placebo Recipients

Released: 16-Dec-2021 10:10 AM EST
Intense meditation brings robust immune system activation
University of Florida

Eight days of intense meditation cause robust activation of the immune system, University of Florida researchers and their colleagues have found. The findings are believed to be the first comprehensive genomic study of how meditation affects the biological processes directly involved in disease development.

Released: 15-Dec-2021 1:40 PM EST
As mutações do SARS-CoV-2 vem e vão, e por isso, a recomendação médica permanece do mesmo modo: vacinem-se
Mayo Clinic

os especialistas da Mayo Clinic afirmam que, independentemente da variante, a prevenção da infecção funciona. As vacinas reduzem e previnem a hospitalização e morte de acordo com o conhecimento atual.

Released: 15-Dec-2021 1:40 PM EST
SARS-CoV-2突变为何反反复复?医生的建议保持不变:请接种疫苗
Mayo Clinic

妙佑医疗国际(Mayo Clinic)的专家表示,无论对于哪种变异株,预防感染的措施都有效。根据现有理解,疫苗可预防并且减少住院和死亡。如果您可以接种疫苗或符合接种加强针的条件,请立即接种。

Released: 15-Dec-2021 1:35 PM EST
لماذا تأتي طفرات فيروس كورونا 2 المسبب لمتلازمة الالتهاب التنفسي الحاد الوخيم (السارز) وتذهب، وتبقى نصيحة الأطباء كما هي: الرجاء أخذ التطعيم؟
Mayo Clinic

مدينة روتشستر، ولاية مينيسوتا- يقول خبراء مايو كلينك، بغض النظر عن المتحور، فإن الوقاية من العدوى تجدي نفعًا. وتقلل اللقاحات من دخول المستشفى والوفاة وتقي منهما بناءً على المعرفة الحالية. إذا كنتَ قادرًا على التطعيم أو مؤهلًا للحصول على جرعة معززة، فقم بذلك الآن.

Released: 15-Dec-2021 1:30 PM EST
Por qué las mutaciones del SARS-CoV-2 van y vienen, y el consejo de los médicos sigue siendo el mismo: vacúnate
Mayo Clinic

Los expertos de Mayo Clinic dicen que, independientemente de la variante, la prevención de la infección funciona. Las vacunas reducen y previenen los casos de hospitalización y muerte, según lo que se sabe hasta ahora. Si reúnes las condiciones para vacunarte o recibir un refuerzo, hazlo ahora.

13-Dec-2021 3:40 PM EST
Mayo Clinic research finds immune system responds to mRNA treatment for cancer
Mayo Clinic

Adding messenger RNA, or mRNA therapy improves the response to cancer immunotherapy in patients who weren't responding to the treatment, Mayo Clinic research shows. Immunotherapy uses the body’s immune system to prevent, control and eliminate cancer. The study is published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

Newswise: Once upon a BCG vaccine
Released: 13-Dec-2021 1:10 PM EST
Once upon a BCG vaccine
La Jolla Institute for Immunology

A long, long time ago, the BCG vaccine was approved for use against tuberculosis (TB), and it's still given to infants today. For generations, the vaccine has saved lives and prevented untold suffering.

Released: 10-Dec-2021 8:00 PM EST
Dr. Ann Shippy, MD Launches Be Resilient, Be Immune Program
Ann Shippy M.D.

Are you worried about the status of your immune system? You're not alone. People all over the globe have been feeling anxious about their health and the health of their loved ones.

   
Released: 10-Dec-2021 3:20 PM EST
Asthma may reduce risk of brain tumors — but how?
Washington University in St. Louis

Asthma has been associated with a lowered risk of brain tumors, and researchers at Washington University School of Medicine in St. Louis now think they know why: Immune cells activated under conditions of asthma are less able to promote the growth of brain tumors. The findings could lead to new therapeutic approaches.

Released: 9-Dec-2021 3:10 PM EST
Why SARS-CoV-2 mutations come and go, and physicians’ advice remains the same: Please vaccinate
Mayo Clinic

Mayo Clinic experts say, regardless of the variant, prevention of infection works. The vaccines reduce and prevent hospitalization and death based on current knowledge. If a person can get vaccinated or is eligible for a booster, do it now. But what about these variants? Why do they show up, and how? Here is what Mayo Clinic experts are saying:

Newswise: Antibodies Discovered at Vanderbilt for Prevention of COVID-19 Granted FDA Emergency Use Authorization
Released: 9-Dec-2021 2:35 PM EST
Antibodies Discovered at Vanderbilt for Prevention of COVID-19 Granted FDA Emergency Use Authorization
Vanderbilt University Medical Center

The combination of two monoclonal antibodies, called Evusheld, was authorized as a pre-exposure prophylaxis to prevent COVID-19 in adults and children 12 years and older who have compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine.

Newswise: Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Released: 9-Dec-2021 11:40 AM EST
Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Rutgers Cancer Institute of New Jersey

Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.

Released: 9-Dec-2021 7:00 AM EST
Drug made from pig intestine helps escape the “trap” of clot-causing immune response
Michigan Medicine - University of Michigan

Two complementary studies show that defibrotide can successfully suppress the formation and progression of neutrophil extracellular traps, or NETs, which are web-like networks of toxic proteins that play a role in forming blood clots and promoting inflammation in several disease, including COVID-19. Researchers say findings may set the stage for defibrotide clinical trials in potentially several diseases.

Released: 8-Dec-2021 4:05 PM EST
Reimagining Immunity in the Eye
Thomas Jefferson University

Immune cells could be doing much more than we think in protecting our eyes – Jefferson researchers uncover new details.

Newswise: Natural infection and vaccination together provide maximum protection against COVID variants
Released: 7-Dec-2021 6:20 PM EST
Natural infection and vaccination together provide maximum protection against COVID variants
University of California, Los Angeles (UCLA), Health Sciences

A combination of vaccination and naturally acquired infection appears to boost the production of maximally potent antibodies against the COVID-19 virus, new UCLA research finds.

Released: 7-Dec-2021 9:00 AM EST
New study investigates immune response and vaccine hesitancy among First Nations communities
McMaster University

The study, called COVID CommUNITY- First Nations, will collect, analyze, and report data relating to COVID-19 vaccine effectiveness and safety, as well as explore hesitancy in three First Nations communities in Canada: Six Nations of the Grand River in southwestern Ontario; Lac La Ronge Indian Band in Saskatchewan; and Wendake in Quebec.

Released: 6-Dec-2021 1:30 PM EST
New marker for better assessing the severity of Covid-19
Ludwig-Maximilians-Universität München (Munich)

Biomedical scientists at LMU have found a new marker in the blood of Covid-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses.

Newswise: Meth use, intimate partner violence weaken immune function in HIV-positive men
Released: 3-Dec-2021 4:05 PM EST
Meth use, intimate partner violence weaken immune function in HIV-positive men
University of California, Los Angeles (UCLA), Health Sciences

Among HIV-positive black and Latino men who have sex with men, the use of methamphetamine combined with intimate partner violence may increase the risk for developing chronic diseases such as cardiovascular disease and other disorders.

Released: 3-Dec-2021 2:50 PM EST
Age-Related Differences in Inflammation May Shed Light on the Limit of Immunotherapies
Sbarro Health Research Organization (SHRO)

Scientists at the Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology, located at Temple University’s College of Science and Technology, working with collaborators in Italy, have described the age-related differences in inflammatory response to an emerging immunotherapy treatment for Non-Small-Cell Lung Cancer (NSCLC) called PD-1 blockade.

Newswise: New vaccine ingredient shows promise
2-Dec-2021 8:05 PM EST
New vaccine ingredient shows promise
La Jolla Institute for Immunology

Scientists at La Jolla Institute for Immunology (LJI) and Massachusetts Institute of Technology (MIT), have found a possible way to improve the effectiveness of COVID-19 vaccines—and any vaccine.



close
2.41246